Intravenous Solution Market

• Growing launches and regulatory approvals for intravenous solution injection to drive growth

New intravenous injection solutions are being introduced by market participants, which is anticipated to accelerate the growth of the global intravenous solutions market in the upcoming years. For example, Baxter International Inc., a global sterile medication production company, announced the FDA approval and commercial launch of premix Bitartrate in 5% Dextrose Injection in September 2021. In adults with severe, acute hypotension, is prescribed to raise blood pressure (low blood pressure). Baxter's formulation is the first and only producer of ready-to-use formulation available in four strengths: 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL).

The Global Intravenous Solution Market Industry is witnessing a shift towards home healthcare services, which is reshaping the demand for IV solutions. As patients increasingly prefer receiving treatments in the comfort of their homes, healthcare providers are adapting their services to accommodate this trend. This shift not only enhances patient satisfaction but also reduces the burden on healthcare facilities. The market is projected to grow substantially, with a potential increase to 33.2 USD Billion by 2035. This emerging trend underscores the importance of flexible and accessible intravenous solutions that cater to the evolving preferences of patients and their families.

The Global Intravenous Solution Market Industry experiences a notable surge in demand due to the increasing prevalence of chronic diseases and the aging population. As healthcare systems worldwide strive to enhance patient care, intravenous solutions are becoming essential for delivering medications, fluids, and nutrients efficiently. In 2024, the market is projected to reach 15 USD Billion, reflecting the growing reliance on IV therapies in hospitals and outpatient settings. This trend is expected to continue, with the market potentially expanding to 33.2 USD Billion by 2035, indicating a robust growth trajectory driven by the need for effective treatment options.

There is a marked increase in awareness regarding the benefits of intravenous therapy within the Global Intravenous Solution Market Industry. Healthcare professionals and patients alike are recognizing the advantages of IV treatments, such as rapid drug delivery and improved hydration. This awareness is driving demand for IV solutions, particularly in emergency care and surgical settings. As educational initiatives proliferate, the market is expected to expand significantly, reaching 15 USD Billion in 2024. The growing acceptance of IV therapy as a standard treatment modality is likely to further propel the market, fostering a culture of proactive health management.

Innovations in the Global Intravenous Solution Market Industry are transforming the landscape of IV therapy. Advanced technologies, such as smart infusion pumps and automated IV compounding systems, enhance the precision and safety of intravenous treatments. These advancements not only improve patient outcomes but also streamline hospital operations, reducing the risk of medication errors. As healthcare providers increasingly adopt these technologies, the market is likely to witness a compound annual growth rate of 7.5% from 2025 to 2035. This growth is indicative of the industry's commitment to integrating cutting-edge solutions that cater to the evolving needs of patients and healthcare professionals.

The Global Intravenous Solution Market Industry benefits significantly from heightened investments in healthcare infrastructure across various regions. Governments and private entities are allocating substantial resources to enhance healthcare facilities, particularly in developing countries. This investment is crucial for expanding access to essential medical services, including intravenous therapies. As a result, the market is poised for growth, with projections indicating a rise to 33.2 USD Billion by 2035. Enhanced infrastructure not only facilitates the distribution of IV solutions but also ensures that healthcare providers can deliver timely and effective treatments to patients, thereby improving overall health outcomes.

By Region, the study provides market insights into Europe, North America, Asia-Pacific, and the Rest of the World. The North American intravenous solution market is expected to grow at a significant CAGR during the projection period, accounting for USD 2.8 billion in 2021. This is due to an increase in the geriatric population, which increases demand for intravenous solutions, the rising incidence of chronic diseases, and the industry's expansion to meet the rising demands caused by the flu and coronavirus pandemics.

North America is a highly developed region with a well-established healthcare infrastructure, which has resulted in an increased demand for IV treatment throughout its life cycle during various stages, such as emergency care or surgery.

In addition, the major countries covered in the intravenous solution market are the United States, Germany, France, Canada, the United Kingdom, India, Spain, Italy, Japan, Australia, China, South Korea, and Brazil.

Figure 3: Intravenous Solution Market Share By Region 2021 (%)

Source: Secondary Research, Primary Research, Market Research Future Database, and Analyst Review

Europe has the world's second-largest intravenous solution market, owing to increasing intravenous solution sales volume in the region due to the region's aging population and correlating growth of the patient pool. This is because the healthcare system has a large patient population, a strong presence of key players, easy drug availability, well-developed healthcare systems, and favorable reimbursement policies. Moreover, technological advancements in the industry and government assistance for the National Health Service and health insurance will likely drive growth in the European intravenous (IV) solutions market.

Further, the U.K. intravenous solution market held the largest market share, and the France intravenous solution market was the fastest-growing market in the European region.

The Asia Pacific intravenous solution market is predicted to expand at the fastest CAGR in the forecast period. The presence of high expenditure by both public and private entities in the research sector, as well as technological advancements and an increasing number of collaborative relationships between various stakeholders, such as the healthcare community, universities, and others, can be attributed to this region's rapid growth. Another important factor anticipated to drive market growth in the Asia Pacific region is the rising prevalence of chronic diseases brought on by unhealthy food consumption patterns and the growing preference for cost-effective care.

The market players constantly expand their facilities, collaborate, acquire companies, and develop new products. These are major strategic initiatives influencing the dynamics of the intravenous solution industry. Additionally, the prevalence of chronic diseases is rising, offering huge opportunities to manufacturers of intravenous solutions. The main industry players concentrate on research and development activities to release new and effective treatments, accelerating the market's growth.

ICU Medical Inc, headquartered in San Clemente, California, develops, manufactures, and sells medical technologies for oncology, vascular therapy, and critical care applications. Smith’s Medical, a division of Smiths Group plc, was acquired by ICU Medical in January 2022. This merger will add Smiths Medical's ambulatory infusion equipment, syringes, vascular access, and medical supplies to ICU Medical's current infusion therapy system, generating an estimated pro forma revenue of about USD 2.5 billion.

The company B. Braun Medical (India) Private Ltd sells medical supplies. The company produces instruments and equipment for medicine, surgery, ophthalmology, diabetes care, infection control, ostomy care, infusion therapy, and veterinary medicine. International customers are served by B. Braun Medical (India). B. Braun Medical received permission from the US FDA in February 2022 to start operations at its brand-new IV saline solution production plant in Daytona Beach, Florida.